• All
• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z

• Z
• Zhai, Qinglian
  Leiden University Medical Center
• PI-027 - EFFECT OF GENETIC VARIANTS IN TSPYL ON THE PHARMACOKINETICS OF CYCLOSPORINE.

  
  Qinglian Zhai
  Favorite
• Zhang, Cindy
  University of Washington
• PII-078 - POPULATION PHARMACOKINETIC MODELING OF CLOFAZIMINE: CHARACTERIZING THE IMPACT OF CRYPTOSPORIDIOSIS-ASSOCIATED DIARRHEA ON ORAL DRUG PHARMACOKINETICS IN HIV-INFECTED ADULTS.

  
  Cindy Zhang
  Favorite
• Zheng, Fudan
  Janssen Pharmaceuticals
• PI-050 - COMPARISON OF THE SYSTEMIC EXPOSURE AND PREDICTED INHIBITION OF PHARMACODYNAMIC CYTOKINE RESPONSE BY SYSTEMIC AND LOCALLY ACTING JAK INHIBITORS.

  
  Fudan Zheng
  Favorite
• Zheng, Ming
  Daiichi Sankyo
• PI-014 - DETERMINATION OF ABSOLUTE BIOAVAILABILITY OF QUIZARTINIB USING A MICROTRACER.
  Ming Zheng
  Favorite
• PII-039 - PHARMACOKINETICS OF INTESTINAL P-GLYCOPROTEIN SUBSTRATE DABIGATRAN ETEXILATE WITH AND WITHOUT CONCOMITANT QUIZARTINIB.
  Ming Zheng
  Favorite
• Zheng, Zicong
  University of Houston
• PII-017 - REVIEW OF BISPECIFIC ANTIBODIES’ IMMUNOGENICITY IN CLINICAL DEVELOPMENT.
  Zicong Zheng
  Favorite
• Zhou, Lian
  Arcus Biosciences
• PII-057 - LIMITED DRUG INTERACTION SUPPORTED BY PBPK MODELLING OF ETRUMADENANT (AB928), A NOVEL DUAL ADENOSINE RECEPTOR ANTAGONIST, UNDER COADMINISTRATION WITH A STRONG CYP3A4 AND P-GP INHIBITOR (ITRACONAZOLE) IN HEALTHY PARTICIPANTS.
  Lian Zhou
  Favorite
• Zhou, Xujia
  University of California, San Francisco
• PT-014 - A GLOBAL PROTEOMICS ANALYSIS OF THE ONTOGENY OF THE BLOOD-BRAIN BARRIER.

  
  Xujia Zhou
  Favorite
• Zhu, Huaqiang
  GenFleet Therapeutics Inc
• EP-032 - A FIRST-IN-HUMAN PHASE I STUDY OF THE GFH312 A RIPK1 INHIBITOR, EVALUATING SAFETY/TOLERABILITY AND PHARMACOKINETICS IN HEALTHY SUBJECTS.
  Huaqiang Zhu
  Favorite
• Zhu, Min
  Regeneron Pharmaceuticals, Inc.
• PII-043 - TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION.

  
  Min Zhu
  Favorite
• PWII-003 - TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION.

  
  Min Zhu
  Favorite
• Zhu, Rui
  Genentech
• PII-085 - POPULATION-BASED EFFICACY MODELING OF OMALIZUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE PERSISTENT INADEQUATELY CONTROLLED ALLERGIC ASTHMA.

  
  Rui Zhu
  Favorite
• Zhu, Xiujuan
  Mayo Clinic
• PII-051 - PHARMACOGENOMICS OF ACAMPROSATE AND NALTREXONE THERAPY RESPONSE IN ALCOHOL USE DISORDER (AUD)
  Xiujuan Zhu
  Favorite
• Zou, Peng
  Daiichi Sankyo Inc.
• EP-033 - A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NON-RANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS.
  Peng Zou
  Favorite
• EP-034 - POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS.
  Peng Zou
  Favorite